Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases

  • Terence C. Chua
  • Lourens Bester
  • Akshat Saxena
  • David L. Morris
Original Paper



To evaluate the role of radioembolization and systemic chemotherapy as a combined modality therapy for unresectable colorectal liver metastases.

Patients and methods

Prospective database of a major yttrium-90 microsphere radioembolization treatment center in Sydney, Australia, that included 140 patients with unresectable colorectal liver metastases was analyzed. Tumor response, overall survival, treatment-related complications and an evaluation of its role as a combined modality therapy with systemic chemotherapy were performed.


One hundred and thirty-three patients (95%) had a single treatment, and seven patients (5%) had repeated treatments. Response following treatment was complete in two patients (1%), partial in 43 patients (31%), stable in 44 patients (31%), and 51 patients (37%) developed progressive disease. Combining chemotherapy with radioembolization was associated with a favorable treatment response (P = 0.007). The median overall survival was 9 (95% CI 6.4–11.3) months with a 1-, 2-, and 3-year survival rate of 42, 22, and 20%, respectively. Primary tumor site (P = 0.019), presence of extrahepatic disease (P = 0.033), and a favorable treatment response (P < 0.001) were identified as independent predictors for survival.


Combined modality therapy appears to improve tumor response rates. Survival is influenced by tumor site, presence of extrahepatic disease, and response to therapy. Yttrium-90 microsphere radioembolization is safe and may best be combined with systemic chemotherapy for patients with unresectable colorectal liver metastases.


Colorectal cancer Liver metastases Microspheres Yttrium-90 Radiotherapy Oxaliplatin Irinotecan 


  1. Adam R, Wicherts DA, de Haas RJ et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27:1829–1835PubMedCrossRefGoogle Scholar
  2. Allen PJ, Nissan A, Picon AI et al (2005) Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg 201:57–65PubMedCrossRefGoogle Scholar
  3. Bengmark S, Hafstrom L (1969) The natural history of primary and secondary malignant tumours of the liver. Cancer 23:198–202PubMedCrossRefGoogle Scholar
  4. Bester L, Salem R (2007) Reduction of arteriohepatovenous shunting by temporary balloon occlusion in patients undergoing radioembolization. J Vasc Interv Radiol 18:1310–1314PubMedCrossRefGoogle Scholar
  5. Campbell AM, Bailey IH, Burton MA (2001) Tumour dosimetry in human liver following hepatic 90Y microsphere therapy. Phys Med Biol 46:487–498PubMedCrossRefGoogle Scholar
  6. Cassidy J, Clarke S, Diaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006–2012PubMedCrossRefGoogle Scholar
  7. Colucci G, Gebbia V, Paoletti G et al (2005) Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 23:4866–4875PubMedCrossRefGoogle Scholar
  8. Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670–1676PubMedCrossRefGoogle Scholar
  9. Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47PubMedCrossRefGoogle Scholar
  10. Fong Y, Kemeny N, Paty P et al (1996) Treatment of colorectal cancer: hepatic metastasis. Semin Surg Oncol 12:219–252PubMedCrossRefGoogle Scholar
  11. Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544PubMedCrossRefGoogle Scholar
  12. Gray B, Van Hazel G, Hope M et al (2001) Randomised trial of SIR-Spheres® plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12:1711–1720PubMedCrossRefGoogle Scholar
  13. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [see comment]. N Engl J Med 350:2335–2342PubMedCrossRefGoogle Scholar
  14. Kemeny N, Fata F (1999) Arterial, portal or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma. J Hepatobiliary Pancreat Surg 6:39–49PubMedCrossRefGoogle Scholar
  15. Khatri VP, Petrelli NJ, Belghiti J (2005) Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 23:8490–8499PubMedCrossRefGoogle Scholar
  16. Kim GP, Sargent DJ, Mahoney MR et al (2009) Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol 27:2848–2854PubMedCrossRefGoogle Scholar
  17. Kuebler JP (2009) Radioembolization of liver metastases in patients with colorectal cancer: a nonsurgical treatment with combined modality potential. J Clin Oncol 27:4041–4042PubMedCrossRefGoogle Scholar
  18. Mary FM, Robert JL, Saad MI et al (2009) Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 115:1849–1858CrossRefGoogle Scholar
  19. Nicolay NH, Berry DP, Sharma RA (2009) Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol 6:687–697PubMedCrossRefGoogle Scholar
  20. Pawlik TM, Schulick RD, Choti MA (2008) Expanding criteria for resectability of colorectal liver metastases. Oncologist 13:51–64PubMedCrossRefGoogle Scholar
  21. Porschen R, Arkenau H-T, Kubicka S et al (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25:4217–4223PubMedCrossRefGoogle Scholar
  22. Salem R, Thurston KG (2006) Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol 17:1251–1278PubMedCrossRefGoogle Scholar
  23. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group [see comment]. N Engl J Med 343:905–914PubMedCrossRefGoogle Scholar
  24. Saltz LB, Rosen LS, Marshall JL et al (2007) Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 25:4793–4799PubMedCrossRefGoogle Scholar
  25. Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019PubMedCrossRefGoogle Scholar
  26. Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311–2319PubMedCrossRefGoogle Scholar
  27. Steele GJ, Ravikumar TS (1989) Resection of hepatic metastases from colorectal metastases: biologic perspectives. Ann Surg 210Google Scholar
  28. Stubbs RS, O’Brien I, Correia MM (2006) Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg 76:696–703PubMedCrossRefGoogle Scholar
  29. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  30. Tomlinson JS, Jarnagin WR, DeMatteo RP et al (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25:4575–4580PubMedCrossRefGoogle Scholar
  31. Vente MA, Wondergem M, van der Tweel I et al (2009) Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 19:951–959PubMedCrossRefGoogle Scholar
  32. Viganò L, Ferrero A, Lo Tesoriere R et al (2008) Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity. Ann Surg Oncol 15:2458–2464PubMedCrossRefGoogle Scholar
  33. Wagner JS, Adson MA, Van Heerden JA et al (1984) The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 199:502–508PubMedCrossRefGoogle Scholar
  34. Wood CB, Gillis CR, Blumgart LH (1976) A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 2:285–288PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Terence C. Chua
    • 1
  • Lourens Bester
    • 2
  • Akshat Saxena
    • 1
  • David L. Morris
    • 1
  1. 1.Hepatobiliary and Surgical Oncology Unit, Department of SurgeryUniversity of New South Wales, St. George HospitalSydneyAustralia
  2. 2.Interventional Oncology, Department of RadiologyUniversity of New South Wales, St. Vincent’s HospitalSydneyAustralia

Personalised recommendations